1. Home
  2. WVE vs BFS Comparison

WVE vs BFS Comparison

Compare WVE & BFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • BFS
  • Stock Information
  • Founded
  • WVE 2012
  • BFS 1993
  • Country
  • WVE Singapore
  • BFS United States
  • Employees
  • WVE N/A
  • BFS N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • BFS Real Estate Investment Trusts
  • Sector
  • WVE Health Care
  • BFS Real Estate
  • Exchange
  • WVE Nasdaq
  • BFS Nasdaq
  • Market Cap
  • WVE 915.6M
  • BFS 830.6M
  • IPO Year
  • WVE 2015
  • BFS 1993
  • Fundamental
  • Price
  • WVE $6.95
  • BFS $35.31
  • Analyst Decision
  • WVE Strong Buy
  • BFS Strong Buy
  • Analyst Count
  • WVE 13
  • BFS 1
  • Target Price
  • WVE $20.15
  • BFS $45.50
  • AVG Volume (30 Days)
  • WVE 1.0M
  • BFS 67.6K
  • Earning Date
  • WVE 08-07-2025
  • BFS 07-31-2025
  • Dividend Yield
  • WVE N/A
  • BFS 6.68%
  • EPS Growth
  • WVE N/A
  • BFS N/A
  • EPS
  • WVE N/A
  • BFS 1.47
  • Revenue
  • WVE $104,939,000.00
  • BFS $274,011,000.00
  • Revenue This Year
  • WVE N/A
  • BFS $7.78
  • Revenue Next Year
  • WVE $1.94
  • BFS $6.78
  • P/E Ratio
  • WVE N/A
  • BFS $24.02
  • Revenue Growth
  • WVE N/A
  • BFS 5.04
  • 52 Week Low
  • WVE $5.04
  • BFS $31.25
  • 52 Week High
  • WVE $16.74
  • BFS $42.39
  • Technical
  • Relative Strength Index (RSI)
  • WVE 53.71
  • BFS 58.84
  • Support Level
  • WVE $6.25
  • BFS $33.50
  • Resistance Level
  • WVE $7.10
  • BFS $34.69
  • Average True Range (ATR)
  • WVE 0.39
  • BFS 0.87
  • MACD
  • WVE -0.01
  • BFS 0.02
  • Stochastic Oscillator
  • WVE 75.27
  • BFS 92.35

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.

Share on Social Networks: